Essays on life sciences, regulation and related subjects.
Access pathways for rare disease treatment in African markets are commercial as well as clinical questions.
South Africa's named-patient (Section 21) route sets the practical conditions under which unregistered medicines reach patients.
Notes from Veltrion Laboratories on regulated, infrastructure-heavy businesses in African healthcare.
SAHPRA registration delay measured as cost to the sponsor, not only as elapsed months.
Why treating Africa as one market is expensive for foreign operators, and what changes when that assumption is dropped.